#United States #Avid Bioservices #CDMO #Tustin #Kerri McCullough Wood

Avid Bioservices Welcomes Kerri McCullough Wood as Chief Commercial Officer

Avid Bioservices, Inc., a prominent player in the biologics sector focused on contract development and manufacturing (CDMO), has made a significant addition to its leadership team with the appointment of Kerri McCullough Wood as Chief Commercial Officer. This strategic move aims to bolster the company's global commercial initiatives and drive growth, particularly in early and late-phase biologics programs.

A Seasoned Leader

Kerri McCullough Wood comes to Avid with nearly 30 years of extensive experience in biopharmaceuticals, particularly in active pharmaceutical ingredients (APIs) and CDMO services. Her most recent role was as the Chief Commercial Officer at TAPI, a division of Teva, where she streamlined operations across 15 countries, focusing on executing commercial strategies that accelerated growth and fostered strong partnerships with major pharmaceutical firms. This background positions her well to lead Avid's commercial efforts.

Strategic Vision for Growth

In her new role at Avid, McCullough Wood will oversee the global commercial organization, which encompasses business development, marketing, and forging strategic partnerships. Her responsibilities will include enhancing the company’s pipeline growth while nurturing client relationships and aligning Avid's commercial strategies with its expanding capabilities in both early-phase development and commercial manufacturing.

“Her arrival is timely; Avid is at a crucial juncture,” remarked Kenneth Bilenberg, Group President and CEO of Avid Bioservices. He highlighted that the company has invested significantly in its early-phase Center of Excellence as well as upgraded its manufacturing capabilities in response to rising demands for U.S.-based biologics development and manufacturing.

Commitment to Excellence

McCullough Wood's appointment aligns with Avid's ongoing mission to support biopharma companies throughout the entire development lifecycle, from early-phase programs to commercial production. The organization is committed to ensuring speed, quality, and operational reliability, making it a trustworthy partner in the ever-evolving CDMO landscape.

“I’m enthusiastic to join Avid during this dynamic period of growth,” commented McCullough Wood. She expressed her eagerness to leverage Avid's established reputation for high-quality service and flexibility as they extend their reach into new markets, deepen client relationships, and bring transformative therapies to patients.

Company Background

Avid Bioservices has carved out a niche as a global CDMO, specializing in mammalian cell-culture manufacturing. Headquartered in the U.S., with an unblemished FDA inspection record, Avid is recognized by biopharmaceutical innovators worldwide for its adaptability, quality, and expertise in navigating complex global regulatory requirements. The organization proudly supports a diverse clientele, ranging from emerging biotech firms to established multinational pharmaceutical corporations, providing comprehensive solutions from development through to commercial supply.

Avid’s Accomplishments

Avid’s operational metrics highlight its success and commitment to the industry:

• - Over 600 manufacturing batches successfully executed.
• - More than 275 commercial batches delivered on a global scale.
• - Seven approved commercial products currently in its portfolio.
• - Ten successful inspections by major regulatory authorities prior to product approvals.

In conclusion, Kerri McCullough Wood's leadership is expected to drive Avid Bioservices toward achieving new heights in the biologics sector, enhancing their ability to deliver essential therapies that can significantly impact patient lives.